$48.13
-0.73-1.49%
最終更新: Oct 23, 4:00 PM
Benzinga
Benzinga
Benzinga
月曜日, 10 26
Benzinga
© 2026 Benzinga | All Rights Reserved
Rigel Pharmaceuticals (RIGL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Rigel Pharmaceuticals (RIGL) は、8 4, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$285M - $295Mの範囲と予想しています。
以前のガイダンスと比較して、Rigel Pharmaceuticalsは売上高予測を以前の範囲である引き上げから$275M - $290Mに引き上げました。
Rigel Pharmaceuticalsは、15から1 9, 2023の間に8 4, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 7 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.17 | $0.85 | $1.25 | $0.85 |
| Actual | $0.88 | $0.44 | $1.12 | $1.46 |
| Surprise | +417.6% | -48.2% | -10.4% | +71.8% |
| Revenue | ||||
| Estimate | $58.6M | $62.0M | $69.1M | $61.8M |
| Actual | $78.7M | $58.8M | $69.8M | $69.5M |
| Surprise | +34.2% | -5.11% | +0.95% | +12.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.94 | $1.02 | $0.49 | $0.80 |
| Revenue | ||||
| Consensus | $79.7M | $87.1M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.88 | $0.17 | 417.6 % |
| Q1 | May 5, 2026 | $0.44 | $0.85 | -48.2 % |
| Q4 | Mar 3, 2026 | $1.12 | $1.25 | -10.4 % |
| Q3 | Nov 4, 2025 | $1.46 | $0.85 | 71.8 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $78.70M | $58.63M | 34.2 % |
| Q1 | May 5, 2026 | $58.80M | $61.97M | -5.11 % |
| Q4 | Mar 3, 2026 | $69.80M | $69.14M | 0.95 % |
| Q3 | Nov 4, 2025 | $69.46M | $61.76M | 12.5 % |